miR-196, an emerging cancer biomarker for digestive tract cancers

49Citations
Citations of this article
37Readers
Mendeley users who have this article in their library.

Abstract

Over the past decade, the emergence of microRNA (miRNA) research has firmly established this molecular family as a key component in cells. MiRNAs, which function as negative gene regulators, participate in multiple biological processes and maintain homeostasis in cells. The dysregulation of miRNA may contribute to numerous human disorders, including cancer. Recently, miR-196 was found to be aberrantly expressed in a wide range of malignant diseases, which suggests that it plays important roles in carcinogenesis. Here, we summarize the current knowledge concerning miR-196 family in cancers. This review includes miR-196 gene structure and aberrant expression in various cancers, and current understanding of numerous functions and regulatory targets of miR-196 in specific cancers. Since miR-196 are consistently found over-expressed in digestive tract cancer tissues, we also reviewed the clinical significance and potential applications of miR-196 in these cancers. We highlight that miR-196 may serve as an emerging cancer biomarker for digestive tract cancers.

Cite

CITATION STYLE

APA

Lu, Y. C., Joseph T Chang, Chan, E. C., Chao, Y. K., Yeh, T. S., Chen, J. S., & Cheng, A. J. (2016). miR-196, an emerging cancer biomarker for digestive tract cancers. Journal of Cancer, 7(6), 650–655. https://doi.org/10.7150/jca.13460

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free